Our AdComm Transcripts service provides you a documentation of the meeting within 3-5 business days after the proceedings.
In order to expedite the service it is important to request this service in advance. The FDA provides transcripts of meetings for free 4-8 weeks after a meeting. Our service is for those that need this text media quickly.
- Oncologic Drugs Advisory Committee
Meeting Date: 2/9/21-2/9/21
The committee will discuss supplemental biologics license application (sBLA) 125514/s-089, for KEYTRUDA (pembrolizumab), submitted by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. The proposed indication (use) for this product is for the treatment of patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
|Location:||Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform.||Related News Links:||Not Available|